MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk

por Knappskog, Stian, Lønning, Per E.
Publicado 2011

Chemosensitivity and p53; new tricks by an old dog

por Lønning, Per E, Knappskog, Stian
Publicado 2012

TP53 status predicts long-term survival in locally advanced breast cancer after primary chemotherapy

por Eikesdal, Hans P., Knappskog, Stian, Aas, Turid, Lønning, Per E.
Publicado 2014

Constitutional Mosaic Epimutations - a hidden cause of cancer?

por Lønning, Per E., Eikesdal, Hans P., Løes, Inger M., Knappskog, Stian
Publicado 2019

The multitude of molecular analyses in cancer: the opening of Pandora’s box

por Russnes, Hege G, Lønning, Per E, Børresen-Dale, Anne-Lise, Lingjærde, Ole C
Publicado 2014

Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines

por Yndestad, Synnøve, Austreid, Eilin, Svanberg, Ida R., Knappskog, Stian, Lønning, Per E., Eikesdal, Hans P.
Publicado 2017

Prevalence of the CHEK2 R95* germline mutation

por Knappskog, Stian, Leirvaag, Beryl, Gansmo, Liv B., Romundstad, Pål, Hveem, Kristian, Vatten, Lars, Lønning, Per E.
Publicado 2016

Impact of the MDM2 splice-variants MDM2-A, MDM2-B and MDM2-C on cytotoxic stress response in breast cancer cells

por Huun, Johanna, Gansmo, Liv B., Mannsåker, Bård, Iversen, Gjertrud Titlestad, Øvrebø, Jan Inge, Lønning, Per E., Knappskog, Stian
Publicado 2017

Assessment of tumor suppressor promoter methylation in healthy individuals

por Poduval, Deepak B., Ognedal, Elisabet, Sichmanova, Zuzana, Valen, Eivind, Iversen, Gjertrud T., Minsaas, Laura, Lønning, Per E., Knappskog, Stian
Publicado 2020

Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy

por Cao, Maria D, Giskeødegård, Guro F, Bathen, Tone F, Sitter, Beathe, Bofin, Anna, Lønning, Per E, Lundgren, Steinar, Gribbestad, Ingrid S
Publicado 2012

Associations between the MDM2 promoter P1 polymorphism del1518 (rs3730485) and incidence of cancer of the breast, lung, colon and prostate

por Gansmo, Liv B., Vatten, Lars, Romundstad, Pål, Hveem, Kristian, Ryan, Bríd M., Harris, Curtis C., Knappskog, Stian, Lønning, Per E.
Publicado 2016

The Functional Roles of the MDM2 Splice Variants P2-MDM2-10 and MDM2-∆5 in Breast Cancer Cells

por Huun, Johanna, Gansmo, Liv B., Mannsåker, Bård, Iversen, Gjertrud T., Sommerfelt-Pettersen, Jan, Øvrebø, Jan Inge, Lønning, Per E., Knappskog, Stian
Publicado 2017

Impact of the APOBEC3A/B deletion polymorphism on risk of ovarian cancer

por Gansmo, Liv B., Sofiyeva, Nigar, Bjørnslett, Merete, Romundstad, Pål, Hveem, Kristian, Vatten, Lars, Dørum, Anne, Lønning, Per E., Knappskog, Stian
Publicado 2021

Differential Inhibition of Ex-Vivo Tumor Kinase Activity by Vemurafenib in BRAF(V600E) and BRAF Wild-Type Metastatic Malignant Melanoma

por Tahiri, Andliena, Røe, Kathrine, Ree, Anne H., de Wijn, Rik, Risberg, Karianne, Busch, Christian, Lønning, Per E., Kristensen, Vessela, Geisler, Jürgen
Publicado 2013

MDM2 promoter SNP55 (rs2870820) affects risk of colon cancer but not breast-, lung-, or prostate cancer

por Helwa, Reham, Gansmo, Liv B., Romundstad, Pål, Hveem, Kristian, Vatten, Lars, Ryan, Bríd M., Harris, Curtis C., Lønning, Per E., Knappskog, Stian
Publicado 2016

Expression of full-length p53 and its isoform Δp53 in breast carcinomas in relation to mutation status and clinical parameters

por Baumbusch, Lars O, Myhre, Simen, Langerød, Anita, Bergamaschi, Anna, Geisler, Stephanie B, Lønning, Per E, Deppert, Wolfgang, Dornreiter, Irene, Børresen-Dale, Anne-Lise
Publicado 2006

Clinical Efficacy and Safety of Bevacizumab Monotherapy in Patients with Metastatic Melanoma: Predictive Importance of Induced Early Hypertension

por Schuster, Cornelia, Eikesdal, Hans P., Puntervoll, Hanne, Geisler, Jürgen, Geisler, Stephanie, Heinrich, Daniel, Molven, Anders, Lønning, Per E., Akslen, Lars A., Straume, Oddbjørn
Publicado 2012

Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer

por Knappskog, Stian, Chrisanthar, Ranjan, Løkkevik, Erik, Anker, Gun, Østenstad, Bjørn, Lundgren, Steinar, Risberg, Terje, Mjaaland, Ingvil, Leirvaag, Beryl, Miletic, Hrvoje, Lønning, Per E
Publicado 2012

NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients

por Borgen, Elin, Rypdal, Maria C., Sosa, Maria Soledad, Renolen, Anne, Schlichting, Ellen, Lønning, Per E., Synnestvedt, Marit, Aguirre-Ghiso, Julio A., Naume, Bjørn
Publicado 2018

MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk

por Gansmo, Liv B., Bjørnslett, Merete, Halle, Mari Kyllesø, Salvesen, Helga B., Romundstad, Pål, Hveem, Kristian, Vatten, Lars, Dørum, Anne, Lønning, Per E., Knappskog, Stian
Publicado 2017